ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
118.815,11
-0,71%
S&P 500
5.439,55
0,15%
US Dollar vs BRL
5,4173
1,25%
Bitcoin
65.573,28
-1,60%
Brent Oil
83,075
1,16%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) Notícias

MRTX

Mirati Therapeutics (MRTX)

Mirati Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRTX
DataHoraFonteTítuloCódigoCompanhia
14/02/202416:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRTXMirati Therapeutics Inc
02/02/202418:05Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MRTXMirati Therapeutics Inc
25/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRTXMirati Therapeutics Inc
23/01/202422:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
23/01/202411:31Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MRTXMirati Therapeutics Inc
23/01/202411:30Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202411:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202410:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRTXMirati Therapeutics Inc
10/01/202410:00PR Newswire (US)European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
27/12/202318:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
06/12/202310:29Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MRTXMirati Therapeutics Inc
10/11/202309:30PR Newswire (US)Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedureNASDAQ:MRTXMirati Therapeutics Inc
06/11/202310:00PR Newswire (US)Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:MRTXMirati Therapeutics Inc
06/11/202309:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRTXMirati Therapeutics Inc
03/11/202318:19PR Newswire (US)Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
02/11/202308:30Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
02/11/202308:30GlobeNewswire Inc.Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNASDAQ:MRTXMirati Therapeutics Inc
23/10/202318:31Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
17/10/202317:00PR Newswire (US)Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)NASDAQ:MRTXMirati Therapeutics Inc
09/10/202311:30Dow Jones NewsTrending: Bristol Myers Squibb Buying Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
09/10/202308:33IH Market NewsMonday’s Wall Street Highlights: Exxon Mobil, Bristol-Myers, Disney, Lockheed Martin, and moreNASDAQ:MRTXMirati Therapeutics Inc
09/10/202307:26Dow Jones NewsMirati Shares Slip Premarket on Bristol Myers TakeoverNASDAQ:MRTXMirati Therapeutics Inc
08/10/202320:21KR Market News브리스톨-마이어스 스퀴브, 48억 달러에 미라티 인수NASDAQ:MRTXMirati Therapeutics Inc
08/10/202319:02Business WireBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202303:56Dow Jones NewsSanofi Considering Acquisition of Mirati Therapeutics, Bloomberg ReportsNASDAQ:MRTXMirati Therapeutics Inc
05/10/202321:33KR Market News사노피, 항암제 제조사 미라티 인수 검토 – 외신NASDAQ:MRTXMirati Therapeutics Inc
05/10/202317:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRTXMirati Therapeutics Inc
02/10/202317:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRTXMirati Therapeutics Inc
27/09/202317:30PR Newswire (US)Mirati To Present Updated Clinical Data at ESMO Congress 2023NASDAQ:MRTXMirati Therapeutics Inc
09/09/202323:35PR Newswire (US)Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung CancerNASDAQ:MRTXMirati Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRTX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
HBOR3
HELBOR ON
BOV
OIBR3
OI ON
BOV
PRIO3
PETRORIO ON
BOV
HAGA3
HAGA ON
BOV
JHSF3
JHSF PART ON
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
TELB4
TELEBRAS PN
BOV
DASA3
DASA ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados